Chronic kidney disease (CKD) on dialysis is a daily challenge, and one of the most persistent is the management of high phosphorus levels. What is RUDIX SUCRO FE? RUDIX SUCRO FE is a phosphate-binding drug developed by Steris Healthcare. It contains chewable tablets of sucroferric oxyhydroxide. 

Why It's Important

Phosphorus is a mineral your body needs in small, balanced amounts. In healthy kidneys, excess phosphorus from food is filtered out and removed through urine. But once kidneys are damaged — particularly in patients undergoing dialysis — this filtering ability drops sharply. Phosphorus from your diet keeps building up in the blood, a condition doctors call hyperphosphatemia.

Dialysis alone usually cannot remove enough phosphorus to keep levels in a safe range. Left unmanaged over months and years, high phosphorus contributes to weakened, brittle bones, abnormal calcium deposits in blood vessels and soft tissue, and a meaningfully higher risk of cardiovascular complications. This is exactly where sucroferric oxyhydroxide chewable tablets, marketed as RUDIX SUCRO FE, become an important part of the treatment plan — not to treat the kidney disease itself, but to control one of its most damaging downstream effects.

This makes RUDIX SUCRO FE less of an optional add-on and more of a long-term protective measure, taken alongside dialysis and dietary phosphorus restriction, to support bone health and reduce strain on the cardiovascular system over time.

Key Benefits of RUDIX SUCRO FE

RUDIX SUCRO FE belongs to a class of medicines called phosphate binders. Unlike medicines that work inside the bloodstream, this one works entirely within the digestive tract, which is part of why it has built a strong real-world reputation among nephrologists and dialysis patients.

What Are the Benefits?

• Effective phosphorus control with a lower pill burden.
• Because sucroferric oxyhydroxide has a high phosphate-binding capacity per tablet, many patients require fewer tablets per day compared to older-generation phosphate binders, which can make day-to-day adherence considerably easier.
• Works directly in the gut, not in the bloodstream.
• The active moiety is practically insoluble and therefore not absorbed and not metabolized, meaning it does its job in the digestive tract and then leaves the body, rather than circulating systemically.
• Minimal impact on systemic iron levels.
• Real-world data on patients using sucroferric oxyhydroxide has shown a favorable safety and tolerability profile, and minimal, if any, systemic iron absorption, even though the tablet itself is iron-based.
• Flexible across treatment stages.
• Observational evidence shows the medicine is effective as monotherapy in phosphate binder-naïve patients, in patients switching from other phosphate binders, or when used in combination with other phosphate binders, giving doctors flexibility depending on where a patient is in their treatment journey.
• Chewable, berry-flavored formulation.
• This is designed for ease of use, particularly important for patients who already manage a heavy daily medication routine and find swallowing large tablets difficult.
• Suitable for a wide age range.
• The therapy is approved for use in adults as well as pediatric patients from 9 years of age and older with chronic kidney disease on dialysis.

Mechanism of Action: How Sucroferric Oxyhydroxide Chewable Tablets Work

Understanding the mechanism behind RUDIX SUCRO FE helps explain why it must be chewed and taken with meals rather than swallowed like a typical tablet.

The active composition, sucroferric oxyhydroxide, is built from a combination of polynuclear iron(III)-oxyhydroxide along with sucrose and starch components. When taken with food, phosphate binding takes place by ligand exchange between hydroxyl groups and/or water and the phosphate ions throughout the physiological pH range of the gastrointestinal tract. In simple terms, the iron-oxyhydroxide structure of the tablet "grabs onto" phosphate molecules from the food you've just eaten while it's still in your stomach and intestines.

Once phosphate is bound to the tablet's iron complex, it is no longer free to be absorbed into the bloodstream. Instead, the bound phosphate-iron compound is eliminated with feces, leaving the body before it ever reaches the blood. Serum phosphorus levels are reduced as a consequence of the reduced dietary phosphate absorption — not through any action on the kidneys themselves.

It's worth noting that the sucrose and starch portions of the tablet are different from the active iron complex — the sucrose and starch components can be digested to glucose and fructose, and maltose and glucose, respectively; these compounds can be absorbed in the blood. This is a relevant consideration for patients managing blood sugar, and one worth discussing with your treating physician.

Indications: Who Should Take RUDIX SUCRO FE

RUDIX SUCRO FE (sucroferric oxyhydroxide chewable tablets) is indicated specifically for the control of serum phosphorus levels in adult and pediatric patients 9 years of age and older with chronic kidney disease on dialysis. It is not intended for general phosphorus management outside this setting and should only be used under the guidance of a nephrologist as part of a structured dialysis care plan.

Efficacy and Clinical Evidence

The clinical foundation behind sucroferric oxyhydroxide chewable tablets is built on both controlled trials and extensive real-world follow-up. One phase 3 clinical study has been performed in patients with chronic kidney disease on dialysis to investigate the efficacy and safety of the molecule, and findings from that program have since been reinforced by post-marketing observational research involving thousands of patients.

In fact, real-world evidence reviews note that retrospective and prospective analyses have been carried out in > 6400 hemodialysis and approximately matched patients, consistently confirming that the medicine reduces serum phosphorus while requiring a lower daily tablet count than many comparator phosphate binders. Importantly, safety monitoring across these studies found that mean changes in iron parameters (ferritin, TSAT and transferrin) and vitamins (A, D, E and K) were generally not clinically meaningful, and the medicine showed a similar gastrointestinal AE profile to sevelamer hydrochloride, a commonly used comparator phosphate binder.

Side Effects of RUDIX SUCRO FE

Like any prescription medicine, RUDIX SUCRO FE can cause side effects, though most patients tolerate it reasonably well when taken correctly with meals. Commonly reported effects include mild gastrointestinal discomfort such as diarrhea, nausea, vomiting, or constipation. A harmless but sometimes alarming effect that patients should be aware of in advance is that this medication may cause discoloration of the urine or feces — this is expected and not a cause for concern on its own.

Serious Side Effects of RUDIX SUCRO FE

While uncommon, certain effects warrant prompt medical attention:

• Signs of an allergic reaction, including rash, itching, swelling, or difficulty breathing
• Severe or persistent abdominal pain
• Unusual fatigue that may indicate a change in iron status, particularly in patients with underlying liver or gastrointestinal conditions
• Signs of iron accumulation in patients with a history of hemochromatosis or other iron-overload conditions, a group that has not been included in the original clinical trial population, so caution and monitoring are advised

If any of these symptoms appear, contact your treating doctor or dialysis care team without delay rather than waiting for a routine follow-up visit.

Available Substitute for RUDIX SUCRO FE

Phosphate binders are not interchangeable on a one-to-one basis, since they differ in binding capacity, tablet burden, and side-effect profile. Commonly used alternative phosphate binders that a nephrologist may consider include calcium-based binders, sevelamer carbonate or sevelamer hydrochloride, and lanthanum carbonate. Any switch between phosphate binders — including a switch to or from RUDIX SUCRO FE — should be made only under medical supervision, since dosing is not directly equivalent across different binder classes.

Dosage Guidelines for RUDIX SUCRO FE

Dosing of sucroferric oxyhydroxide chewable tablets is individualized based on serum phosphorus levels and must be guided by a treating physician. As a general clinical reference:

• The typical starting dose for adults is 3 tablets (1500 mg) per day, taken as 1 tablet (500 mg) 3 times daily with meals.
• For pediatric patients aged 12 years and older, the recommended starting regimen mirrors the adult dose, while the recommended starting dose for pediatric patients 9 to less than 12 years of age is one 500 mg tablet two times daily with meals.
• Dosage is then individually titrated; doctors typically titrate the dose in increments of 1 tablet (500 mg) each day every 2–4 weeks until the target serum phosphorus concentration is reached, with regular blood monitoring.
• The tablet must always be chewed or crushed; it should never be swallowed whole, and should be taken with meals to coincide with dietary phosphate intake.
• If a dose is missed, resume dosing with the next meal; do not attempt to replace a missed dose.

Precautions & Warnings While Using RUDIX SUCRO FE

• Caution in specific patient groups: Patients with peritonitis during peritoneal dialysis, significant gastric or hepatic disorders, a history of major gastrointestinal surgery, or a history of hemochromatosis or other diseases with iron accumulation were not studied in clinical trials and require closer monitoring if prescribed this medicine.
• Pregnancy and breastfeeding: Patients should inform their doctor if pregnant; while it is considered unlikely to pass into breast milk, breastfeeding patients should still consult their doctor before use.
• Drug interaction awareness: Sucroferric oxyhydroxide can interact with certain other medicines. For example, it may decrease the level or effect of vadadustat through drug binding in the gastrointestinal tract, and certain antiviral agents like tecovirimat may have increased absorption when taken alongside it. Always share a complete medication list with your doctor and pharmacist.
• Storage instructions: Tablets should be stored at 25ºC (77ºF), with excursions permitted to 15–30ºC, and the container should be kept tightly closed to protect tablets from moisture.
• Diet adherence: Patients are advised to continue following their prescribed renal diet alongside RUDIX SUCRO FE, since the medicine works in combination with — not as a replacement for — dietary phosphate control.
• Diabetic patients: Because the tablet's non-iron components break down into absorbable sugars, patients managing diabetes should discuss this with their physician as part of overall glucose monitoring.

Sucroferric Oxyhydroxide Price and Buyer Considerations

For patients comparing the sucroferric oxyhydroxide price across brands, it's important to evaluate not just per-strip cost but also the number of tablets needed daily, since a medicine with a lower per-day pill burden can offer better long-term value despite a higher individual tablet price. RUDIX SUCRO FE is manufactured by Steris Healthcare Pvt Ltd under WHO-GMP certified standards, offering quality assurance for patients and caregivers seeking a dependable, prescription-only phosphate binder for long-term dialysis care.

Conclusion

Managing hyperphosphatemia is one of the most important — and most overlooked — parts of long-term dialysis care. RUDIX SUCRO FE, built on the well-studied composition of sucroferric oxyhydroxide chewable tablets, offers a clinically backed, lower-pill-burden option for keeping serum phosphorus within a safer range, helping protect bone health and reduce cardiovascular strain over time. As with any prescription phosphate binder, the right dose, the right precautions, and regular blood monitoring make all the difference between a medicine that simply manages numbers and one that genuinely protects long-term health. Always use RUDIX SUCRO FE strictly under the guidance of your nephrologist or dialysis care team.

Frequently Asked Questions

1. What is RUDIX SUCRO FE used for?

RUDIX SUCRO FE (sucroferric oxyhydroxide chewable tablets) is used to control high serum phosphorus levels in adult and pediatric patients aged 9 years and above who are on dialysis due to chronic kidney disease.

2. What is the composition of RUDIX SUCRO FE?

Each chewable tablet is composed of sucroferric oxyhydroxide, an iron-based phosphate binder combined with sucrose and starch excipients.

3. How should I take sucroferric oxyhydroxide chewable tablets?

The tablet must be chewed or crushed — never swallowed whole — and taken with meals, since it works by binding dietary phosphate in the gut.

4. What is the typical starting dose of RUDIX SUCRO FE?

For adults, the typical starting dose is 1 tablet (500 mg) taken three times daily with meals, totaling 1500 mg per day, which may be adjusted by your doctor based on phosphorus levels.

5. What are the common side effects of sucroferric oxyhydroxide?

The most commonly reported effects are mild gastrointestinal symptoms such as diarrhea, nausea, or constipation, along with harmless discoloration of urine or stool.

6. Does RUDIX SUCRO FE affect blood iron levels?

Real-world studies show minimal systemic iron absorption with sucroferric oxyhydroxide, though patients with a history of iron-overload conditions should be monitored closely by their doctor.

7. What is the sucroferric oxyhydroxide price compared to other phosphate binders?

Pricing varies by brand and pack size; patients should weigh per-tablet cost alongside daily pill burden, as a lower pill count can offset a higher individual tablet price over time.

8. Can RUDIX SUCRO FE be taken without a prescription?

No. RUDIX SUCRO FE is a prescription-only medicine and must be used strictly under medical supervision as part of a dialysis treatment plan.

9. Is there a substitute available for RUDIX SUCRO FE?

Yes, alternative phosphate binders such as sevelamer, lanthanum carbonate, or calcium-based binders exist, but switching between them should only be done under a nephrologist's guidance.

10. Who manufactures RUDIX SUCRO FE?

RUDIX SUCRO FE is marketed by Steris Healthcare Pvt Ltd and manufactured under WHO-GMP certified standards.

Product Information

Brand Name: RUDIX SUCRO FE (Steris Healthcare Pvt Ltd) Composition: Sucroferric Oxyhydroxide Chewable Tablets Formulation: Chewable Tablet Marketed By: Steris Healthcare Pvt Ltd Regulatory Standard: WHO-GMP Certified Schedule: Valid Prescription Required (Prescription Only)

For Further Information: Mail Us: contact@sterispharma.com or info@sterispharma.com Call Now: +918824175417, +919982524671

Buy Now